Tens of thousands of doses of cutting-edge cancer therapies, which could help save lives and tackle some of the hardest-to-treat forms of cancer, are set to be produced from hundreds of tonnes of reprocessed uranium, generated from historic processing of spent nuclear reactor fuel.

The work is being made possible thanks to a landmark agreement announced on 16 December between the cutting-edge biotech firm Bicycle Therapeutics, and the UK Nuclear Decommissioning Authority.

Bicycle, based in Cambridge, England, was co-founded by one of the luminaries of British science, Sir Greg Winter, who was honoured with the Nobel Prize for Chemistry in 2018.